📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes. (2022)

First Author: Sekeres MA

Attributed to: University of Oxford – Confidence in Concept 2019 funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1007/s00277-022-04853-4

PubMed Identifier: 35488900

Publication URI: http://europepmc.org/abstract/MED/35488900

Type: Journal Article/Review

Volume: 101

Parent Publication: Annals of hematology

Issue: 8

ISSN: 0939-5555